Natalizumab treatment for early multiple sclerosis-like symptoms
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 2 study tests natalizumab to treat people who have had a first episode of symptoms suggestive of multiple sclerosis. It aims to see whether the treatment can help after early “demyelination” changes are seen on brain MRI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 55 years old
- You have had a first episode that doctors think could be “clinically isolated syndrome” or definite multiple sclerosis
- Your brain MRI shows at least two spots (lesions) that look like demyelination
- You can attend study visits and complete the required tests
- You are not allergic to Tyruko® (natalizumab) or its ingredients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
This early-phase trial tests a new type of immune cell therapy (CAR-T) designed to target and calm the immune system in people with certain autoimmune neurological diseases that haven't improved with standard care. The goal is to see if it's safe and if it can reduce disease activity.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.